

# CIG Pannonia

Recommendation: Neutral (unch.)

Target price (e-o-y): HUF 340 (unch.)

Share price: HUF 333

Share price as of 23/02/2021	HUF 333	Bloomberg	PANNONIA HB
Number of diluted shares [million]	94.4	Reuters	CIGP.BU
Market capitalization [HUF bn/EUR mn]	31,445/89.7	Free float	49%
Daily turnover 12M [HUF million]	0.08	52 week range	HUF 137 – 388

## Back to growth under new leadership

- CIG Pannonia Life Insurance (Pannonia) reported in Q1/21 HUF 383mn after-tax profit compared to HUF 243mn in the same period a year earlier. The increase of after-tax profit was mainly attributable to higher GWP (+19% YoY), lower net claims and stricter control over OpEx (+5% YoY), with acquisition costs declining by 3% YoY.
- Comprehensive income came to HUF -67mn versus HUF -1.19bn in the same period a year ago. Other comprehensive income included a HUF 450mn decrease in the fair value of available-for-sale financial assets, of which HUF 205mn is the unrealized loss on OPUS shares held by Pannonia and the remaining HUF 245mn was the unrealized loss on government securities.
- Life insurance business w/o subsidiaries generated after-tax profit of HUF 444mn (+22% YoY), while individual non-life insurance operation (EMABIT) had a loss of HUF 50mn versus HUF 73mn loss YoY. It should be noted that, at the end of 2020 Pannonia took steps at the operational level to restart EMABIT, with providing the required Group-level warranty elements followed by the recovery plan stabilize EMABIT's capital position. Also importantly, the criteria for the Italian guarantee portfolio are no longer valid due to the unlikely scenario of the sale of the portfolio. Consequently, definition of IFRS 5 held for sale is no longer appropriate for the entire non-life segment. The held for sale criteria can only be interpreted for the smaller Hungarian and Polish extended warranty and gap casco portfolio that are still actually on sale. Profit before tax on these non-life assets was HUF 32mn in Q1/21. Loss of the other segments was HUF 11mn, or HUF 37mn less than in the same period of the previous year.

### Breakdown of after tax profit (HUF mn)

	Life	Non-life*	Other	Total
After tax profit	444	-50	-11	383
Ch. YoY	25%	32%	77%	58%

*Note: Non-life operation's after-tax profit includes the results from assets held for sales.  
 Source: CIG Pannonia, Concorde's estimate*

- Pannonia's life insurance business remained financially stable and fundamentally solid, with a solvency II capital adequacy ratio staying as high as 340%. The consolidated capital adequacy ratio was 344% at the end of March, 2021.

#### Equity Analyst

Attila Vágó

+361 489 2265

a.vago@con.hu

Alkotás Point


55-61 Alkotás utca,

H-1123 Budapest

www.con.hu

- In the life insurance segment, the total annualized amount of new sales was HUF 1.06bn, 25% higher than in the same period a year earlier, driven by increasing premium of group contracts, on which the commission rate is relatively lower compared to other products. The annualized amount of traditional life insurance new sales rose by 25% YoY, which might be attributed to increasing group insurance policy sales, while the amount of new sales of unit-linked products declined by 8% YoY mainly due to the COVID-19 pandemic.
- As a whole, life insurance GWP rose by 18% YoY from HUF 4.15bn to HUF 4.9bn in Q1/21. GWP of unit-linked life insurance reached HUF 3.56bn (thereof 36%, ie. HUF 1.28bn was pension insurance policies), HUF 1.27bn were traditional life products (thereof HUF 0.3bn came from pension insurance policies), and HUF 0.08bn were health insurance policies. GWP from renewals was HUF 3.16bn (+8% YoY), while GWP from the first annual premiums of policies sold was HUF 0.65bn (+32% YoY). Top-up and single premiums amounted to HUF 1.1bn (+50% YoY), accounting for 22% of total life insurance GWP in Q1/21 compared to 18% YoY. Renewal ratio improved QoQ from 86% to 92%.

GWP breakdown in the life insurance segment (HUF bln)




Source: Pannonia, Concorde estimate

- Non-life GWP dropped by 96% YoY to HUF 74mn mainly because of the divestment of some major activities.
- Although 12-month rolling GWP continued sliding for the fourth consecutive quarter due to deteriorating non-life premium income as a consequence of divestments, but the improved renewal ratio and new life business sales are supportive to consolidated GWP.

Quarterly consolidated GWP breakdown (HUF bn)

12-m rolling GWP breakdown (HUF bn)



Source: Pannonia, Concorde estimate.

- The other operating income of HUF 232mn came mainly from fund management operation (HUF 144mn), which decreased by 8% YoY due to a previously sold unit-linked product portfolio.
- Investment results were positive at HUF 5.63bn in Q1/21 (vs. HUF -7.53bn in Q1/20) as a result of an unprecedented recovery in the stock and bond market valuation after a collapse globally triggered by the outbreak of the coronavirus pandemic early last year. In contrast, in the first quarter of 2021 inflation expectations increased, which led to rising bond yields and therefore lower bond prices.
- Operating costs rose by 5% YoY in Q1/21 and accounted for 32% of GWP (vs. 28% in Q4/20 and 36% in Q1/20), of which fees, commissions and other acquisition costs represented 59% (vs. 63% in Q4/20 and 64% in Q1/20), while admin costs and other expenses (mainly provisions) accounted for the rest. Acquisition costs decreased by 3% YoY mainly due to the increasing sale of traditional insurance products with lower commission rates, and accounted for ca. 88% of annualized premium of new sales compared to 115% YoY.
- Net claims and related settlement expenses dropped by 5% YoY in Q1/21 partly due to a decrease in non-life segment expenses, and also due to life segment claims expenditures mainly due to the surrenders of unit-linked products.
- The amount of net change in reserves was HUF 4.66bn, which is made up almost entirely by the increase of unit-linked life insurance reserves.
- As for life insurance policies sold in 2020 the share of the tied agent network is 11% (vs. 13% in Q1/20), independent brokers bring in 50% (vs. 36% in Q4/20) and the bank and other business developments represented 39% of new sales (vs. 51% in Q4/20).
- Pannonia appears to have delivered on its strategy of focusing external growth and transparency. We are also confident that CIG Pannonia remains on track to achieve efficiency gains through diversification of its product mix and distribution channels. We hold the view that the first quarter results should serve reason for investors to place more confidence in Pannonia’s new strategy and management’s ability to develop growth of businesses on a sustainable basis. **We maintain our TP at HUF 340 a share and reiterate our Neutral rating on Pannonia.**

## Disclaimer

**Concorde Securities Ltd. does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interests that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. For analysts' certification and other important disclosures, please refer to the "Disclaimer" section at the end of this report.**

### DISCLAIMER I.

This research report has been prepared by Concorde Securities Ltd., a full-service Hungarian investment banking, investment management and brokerage firm. Concorde Securities Ltd. is under the supervision of the National Bank of Hungary in its capacity as financial supervisory authority.

Concorde Securities Ltd. is registered in Hungary and does not have any subsidiaries, branches or offices outside of Hungary. Therefore we are not allowed to provide direct investment banking services to US investors and restrictions may apply to our potential investment banking services according to your country's jurisdiction.

Our salespeople, traders and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are their own and may be contrary to the opinions expressed in our research products, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed by our analysts or traders.

Our research, sales and trading professionals are paid based on the profitability of the respective divisions of Concorde Securities Ltd., which from time-to-time may include revenues from the firm's capital market activity. Concorde Securities Ltd. does not prohibit analysts, salespeople and traders from maintaining a financial interest in the securities or futures of any companies that they cover or trade on their clients' behalf in strict compliance with the Hungarian Capital Markets Act.

### ANALYSTS CERTIFICATION

The research analysts undersigned and responsible for the preparation of this report hereby certify that (i) the views expressed in this research report accurately reflect their personal views about any and all of the securities or issuers referred to in this research report; (ii) no part of the analysts' compensation was, is or will be directly or indirectly related to the specific recommendation or views expressed in this report and (iii) no part of their compensation is tied to any specific investment transactions performed by Concorde Securities Ltd.

Name and job title of individuals involved in the production of this report are disclosed at the end of this report.

Concorde Securities Ltd. is a leading manager and underwriter of Hungarian equity offerings. We have investment banking and other business relations with a substantial percentage of the companies traded on the Budapest Stock Exchange and covered by our research department. Concorde Securities Ltd, its directors and employees may have a position in these securities, which may change at any time.

Concorde Securities Ltd. acted as Lead Manager of the private and public share placement of the shares of FHB in 2003, Masterplast in 2012 and Duna House in 2016. Concorde Securities Ltd. acted as the Co-lead Manager of Gedeon Richter's exchangeable bond issue in September 2004. Concorde Securities Ltd. has provided financial advice to Magyar Telekom.

### EXPLANATION OF RATINGS AND METHODOLOGY

Rating	Trigger
Buy	Total return is expected to exceed 20% in the next 12 months
Accumulate	Total return is expected to be in the range of 10-20%
Neutral	Total return is expected to be in the range of 10%-(-10%)
Reduce	Total return is expected to be in the range of -10-(-20%)
Sell	Total return is expected to be lower than -20%
Under Revision	The stock is put Under Revision if the covering analyst considers new information may change the valuation materially and if this may take more time.

Coverage in transition

Coverage in transition rating is assigned to a stock if there is a change in analyst.

### **Securities prices:**

Prices are taken as of the previous day's close on the home market unless otherwise stated.

### **Valuations and risks:**

Analysis of specific risks to set stock target prices highlighted in our investment case(s) are outlined throughout the report. For details of methodologies used to determine our price targets and risks related to the achievement of the targets referred to in the main body of the report or at [Rating Methodology](https://www.con.hu/wp-content/uploads/2016/04/Methodology_concorde_research.pdf?tstamp=201710021038) on our website, visit ([https://www.con.hu/wp-content/uploads/2016/04/Methodology\\_concorde\\_research.pdf?tstamp=201710021038](https://www.con.hu/wp-content/uploads/2016/04/Methodology_concorde_research.pdf?tstamp=201710021038))

### **Research disclosures:**

Concorde Securities Ltd. may have published other investment recommendations in respect of the same securities/instruments recommended in this report during the preceding 12 months. Disclosure of previous investment recommendations produced by Concorde Securities Ltd. in the previous 12 months can be found at [Rating history](https://www.con.hu/wp-content/uploads/2016/04/Rating-history.pdf?tstamp=201710021038). (<https://www.con.hu/wp-content/uploads/2016/04/Rating-history.pdf?tstamp=201710021038>)

#### *GENERAL*

This report is provided for information purposes only and does not represent an offer for sale, or the solicitation of any offer to buy or sell any securities.

The information, and any opinions, estimates and forecast have been obtained from sources believed by us to be reliable, but no representation or warranty, express or implied is made by us as to their accuracy or completeness. The information, opinions, estimates and forecasts may well be affected by subsequent changes in market conditions. This document may not be reproduced in whole or in part, or published for any purpose.

REPRODUCTION OR REBROADCAST OF ANY PORTION OF THIS RESEARCH REPORT IS STRICTLY PROHIBITED WITHOUT THE WRITTEN PERMISSION OF CONCORDE SECURITIES LTD.

### **DISCLAIMER II.**

This research/commentary was prepared by the assignment of Budapest Stock Exchange Ltd. (registered seat: 1054 Budapest, Szabadság tér 7. Platina torony I. ép. IV. emelet; company registration number: 01-10-044764, hereinafter: BSE) under the agreement which was concluded by and between BSE and Concorde Securities Ltd. (registered seat: H-1123 Budapest Alkotás utca 50., company registration number: 01-10-043521, hereinafter: Investment Service Provider)

BSE shall not be liable for the content of this research/commentary, especially for the accuracy and completeness of the information therein and for the forecasts and conclusions; the Service Provider shall be solely liable for these. The Service Provider is entitled to all copyrights regarding this research/commentary however BSE is entitled to use and advertise/spread it but BSE shall not modify its content.

This research/commentary shall not be qualified as investment advice specified in Point 9 Section 4 (2) of Act No. CXXXVIII of 2007 on Investment Firms and Commodity Dealers and on the Regulations Governing their Activities. Furthermore, this document shall not be qualified as an offer or call to tenders for the purchase, sale or hold of the financial instrument(s) concerned by the research/commentary.